Skip to main content

Advertisement

Figure 1 | Journal of Translational Medicine

Figure 1

From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Figure 1

CONSORT diagram. Scheme showing an HLA-A-status double-blind, biologically-randomized phase ΙI study of five therapeutic epitope-peptides combined with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). CRC, colorectal cancer; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine and oxaliplatin; HLA, human leukocyte antigen.

Back to article page